By the end of this year, Pfizer and Moderna’s doses are sufficient to vaccinate up to 6% of the American population against COVID-19.
But a simple change will double the number of people vaccinated. Do not take the medicine twice first, but take the medicine first. The single shot is not effective, but it can make the immune system resist a certain degree of infection of the coronavirus. At least in the short term, diversifying supply will provide more protection for millions of people and potentially save more lives.
Christopher Gill, an infectious disease expert at Boston University, said of the current daily mortality rate of COVID-19: “Such a high daily mortality rate is unprecedented.” “It is time to consider spreading the vaccine as widely as possible. And as soon as possible to cover as many nursing home residents and medical staff as possible to reduce mortality.”
Moderna and Pfizer did not test the comparison between their one-dose vaccine and two-dose vaccine, but experts can read between existing data. The initial injection of Moderna vaccine takes two weeks to stimulate an immune response, and the recipient will be boosted after 28 days. Epidemiologist Michael Mina and columnist Zeynep Tufecki wrote in the report that during this period, the vaccine was effective in preventing symptomatic COVID-19, reaching 92%. New York Times. After the second dose started, the vaccine’s effective rate was 94%. Gill said: “Two doses are better, but not surprising.” It is not clear how a single dose of Pfizer’s vaccine compares with two doses (95% effective dose), but Gill said the data shows that the effectiveness of a single injection is about 90%.
Some experts are wary of this suggestion, but not because of the difference in efficacy. Without conclusive evidence, they cannot recommend different dosage guidelines. “We don’t know anything about the duration or intensity of an immune response. [Pfizer or Moderna] Vaccines,” Barry Bloom, a public health expert at Harvard University’s Chenhe School of Public Health, said at a press conference.
Without research, experts cannot predict when a single dose of protection will run out. Six months after being offline, assuming that protection has actually been lost, vaccinated people may enter crowded areas, and health officials did not know until it was too late. Bloom said: “If scientists start to guess what the evidence is, rather than on the basis of evidence, it may save more lives in a short period of time.” “But when it fades away, we will encounter a very difficult problem. problem.”
William Hanage, an epidemiologist at Harvard’s Chenhe School of Public Health, recommends waiting for clinical trials to change the dose. He said at the same press conference as Bloom: “Once evidence is collected, then we will be more capable of making such recommendations.” But Jill of Boston University worries that waiting for trial will kill him. He said: “We can no longer wait six months.” “We have to deal with the information we have.”
If healthcare providers are to move forward with a single dose without data support, Hannage fears that the public may be less willing to accept the COVID-19 vaccine. Some people are already worried that the company will rush to conduct vaccine trials, and a vaccine program that has no evidence of basis may further undermine trust. Moreover, although early vaccinators can be strengthened when supplies are limited, it is difficult to convince people to get vaccinated again, especially when follow-up actions take months or years. For this reason, the best way to distribute the COVID-19 vaccine may be to develop more vaccines and use them as indicated on their test labels.
Gallery: Research shows that this strange symptom may be your only sign of COVID (Best Life)